BBO-11818 in Adult Subjects With KRAS Mutant Cancer - KONQUER‑101 Study
A first in human study to evaluate the safety and preliminary antitumor activity of BBO‑11818, a pan‑KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
BBO‑11818 is a pan‑KRAS inhibitor that could provide a new treatment option for patients with KRAS‑mutant solid tumors, which currently have limited targeted therapies.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT